DNA Repair Pathways in Clinical Practice: Lessons From Pediatric Cancer Susceptibility Syndromes
The DOI matches its Crossref record; 103 of the 103 references it cites were found in a registry or an index.
Abstract
Human cancers exhibit genomic instability and an increased mutation rate due to underlying defects in DNA repair. Cancer cells are often defective in one of six major DNA repair pathways, namely: mismatch repair, base excision repair, nucleotide excision repair, homologous recombination, nonhomologous endjoining and translesion synthesis. The specific DNA repair pathway affected is predictive of the kinds of mutations, the tumor drug sensitivity, and the treatment outcome. The study of rare inherited DNA repair disorders, such as Fanconi anemia, has yielded new insights to drug sensitivity and treatment of sporadic cancers, such as breast or ovarian epithelial tumors, in the general population. The Fanconi anemia pathway is an example of how DNA repair pathways can be deregulated in cancer cells and how biomarkers of the integrity of these pathways could be useful as a guide to cancer management and may be used in the development of novel therapeutic agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Mutation and cancer: statistical study of retinoblastoma
Knudson, A. G. (1971) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.68.4.820 · Cited by 7,612
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Instability and decay of the primary structure of DNA
Lindahl, T. (1993) · Nature · doi:10.1038/362709a0 · Cited by 5,679
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Genetic instabilities in human cancers
Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1998) · Nature · doi:10.1038/25292 · Cited by 4,168
Genome maintenance mechanisms for preventing cancer
Hoeijmakers, J. H. J. (2001) · Nature · doi:10.1038/35077232 · Cited by 3,939
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688
DNA double-strand breaks: signaling, repair and the cancer connection
Khanna, K. K., & Jackson, S. P. (2001) · Nature Genetics · doi:10.1038/85798 · Cited by 2,455
Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2
King, M.-C., Marks, J. H., & Mandell, J. B. (2003) · Science · doi:10.1126/science.1088759 · Cited by 2,229
Cited by
Stratton, M. R., Campbell, P. J., & Futreal, P. A. (2009) · Nature · doi:10.1038/nature07943 · Cited by 3,449
Genomic instability — an evolving hallmark of cancer
Negrini, S., Gorgoulis, V. G., & Halazonetis, T. D. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2858 · Cited by 2,397
Mechanism of Eukaryotic Homologous Recombination
San Filippo, J., Sung, P., & Klein, H. (2008) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.77.061306.125255 · Cited by 1,681
Repair Pathway Choices and Consequences at the Double-Strand Break
Ceccaldi, R., Rondinelli, B., & D’Andrea, A. D. (2016) · Trends in Cell Biology · doi:10.1016/j.tcb.2015.07.009 · Cited by 1,499
“The tumor is thus dependent on this alternative pathway for survival, inhibition of which will specifically kill the malignant cells (synthetic lethality) with little effect on normal cells [102].”
Self-citationGenomic and Epigenetic Instability in Colorectal Cancer Pathogenesis
Grady, W. M., & Carethers, J. M. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.07.076 · Cited by 960
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
Konstantinopoulos, P. A., Ceccaldi, R., Shapiro, G. I., & D'Andrea, A. D. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0714 · Cited by 945
Self-citationHomologous-recombination-deficient tumours are dependent on Polθ-mediated repair
Ceccaldi, R., Liu, J. C., Amunugama, R., Hajdu, I., Primack, B., Petalcorin, M. I. R., O’Connor, K. W., Konstantinopoulos, P. A., Elledge, S. J., Boulton, S. J., et al. (2015) · Nature · doi:10.1038/nature14184 · Cited by 903
Self-citationATM and ATR as therapeutic targets in cancer
Weber, A. M., & Ryan, A. J. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.12.001 · Cited by 635
Chromatin Remodeling at DNA Double-Strand Breaks
Price, B. D., & D’Andrea, A. D. (2013) · Cell · doi:10.1016/j.cell.2013.02.011 · Cited by 588
Self-citationMenear, K. A., Adcock, C., Boulter, R., Cockcroft, X.-L., Copsey, L., Cranston, A., Dillon, K. J., Drzewiecki, J., Garman, S., Gomez, S., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8001263 · Cited by 584
Mechanisms of Chemoresistance to Alkylating Agents in Malignant Glioma
Sarkaria, J. N., Kitange, G. J., James, C. D., Plummer, R., Calvert, H., Weller, M., & Wick, W. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1719 · Cited by 373
Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond
Curtin, N. J., & Szabo, C. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2013.01.006 · Cited by 369
The role of PARP in DNA repair and its therapeutic exploitation
Javle, M., & Curtin, N. J. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.382 · Cited by 320
RAD18 transmits DNA damage signalling to elicit homologous recombination repair
Huang, J., Huen, M. S. Y., Kim, H., Leung, C. C. Y., Glover, J. N. M., Yu, X., & Chen, J. (2009) · Nature Cell Biology · doi:10.1038/ncb1865 · Cited by 310
DNA Damage Response Genes and the Development of Cancer Metastasis
Broustas, C. G., & Lieberman, H. B. (2014) · Radiation Research · doi:10.1667/rr13515.1 · Cited by 275
Rainey, M. D., Charlton, M. E., Stanton, R. V., & Kastan, M. B. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0763 · Cited by 266
Hussain, S., Zhang, Y., & Galardy, P. (2009) · Cell Cycle · doi:10.4161/cc.8.11.8739 · Cited by 260
van Vugt, M. A. T. M., Gardino, A. K., Linding, R., Ostheimer, G. J., Reinhardt, H. C., Ong, S.-E., Tan, C. S., Miao, H., Keezer, S. M., Li, J., et al. (2010) · PLoS Biology · doi:10.1371/journal.pbio.1000287 · Cited by 232
“Radiotherapy as well as many types of anti-tumor chemotherapy are believed to preferentially kill tumor cells by generating extensive amounts of DNA damage that promotes cell death in checkpoint-compromised tumors, but not in the surrounding non-neoplastic tissue where the checkpoint and repair pathways are intact [10…”
A mobile threat to genome stability: The impact of non-LTR retrotransposons upon the human genome
Konkel, M. K., & Batzer, M. A. (2010) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2010.03.001 · Cited by 190
“Deficiencies involving HR have been associated with cancer development [90, 91].”
BackgroundMalignant pleural mesothelioma: history, controversy and future of a manmade epidemic
Røe, O. D., & Stella, G. M. (2015) · European Respiratory Review · doi:10.1183/09059180.00007014 · Cited by 185
Hematopoietic stem cell defects in mice with deficiency of Fancd2 or Usp1
Parmar, K., Kim, J., Sykes, S. M., Shimamura, A., Stuckert, P., Zhu, K., Hamilton, A., Deloach, M. K., Kutok, J. L., Akashi, K., et al. (2010) · Stem Cells · doi:10.1002/stem.437 · Cited by 113
“FA patients have an increased risk of developing malignancies, particularly acute myelogenous leukemia and squamous cell carcinomas [5,6].”
BackgroundSelf-citationCrawford, S. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00068 · Cited by 108
Numerical chromosomal instability mediates susceptibility to radiation treatment
Bakhoum, S. F., Kabeche, L., Wood, M. D., Laucius, C. D., Qu, D., Laughney, A. M., Reynolds, G. E., Louie, R. J., Phillips, J., Chan, D. A., et al. (2015) · Nature Communications · doi:10.1038/ncomms6990 · Cited by 95
Transcriptional repression of DNA repair genes is a hallmark and a cause of cellular senescence
Collin, G., Huna, A., Warnier, M., Flaman, J.-M., & Bernard, D. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0300-z · Cited by 71
Si, Y., Pulliam, A. C., Linka, Y., Ciccone, S., Leurs, C., Yuan, J., Eckermann, O., Fruehauf, S., Mooney, S., Hanenberg, H., et al. (2008) · Blood · doi:10.1182/blood-2007-07-102947 · Cited by 28
Mutations and Lethality in Simulated Prebiotic Networks
Inger, A., Solomon, A., Shenhav, B., Olender, T., & Lancet, D. (2009) · Journal of Molecular Evolution · doi:10.1007/s00239-009-9281-y · Cited by 14
Metadata
- Authors
- Kennedy, R. D., & D'Andrea, A. D.
- Venue
- Journal of Clinical Oncology
- Published
- 2006-08-10
- Volume
- 24
- Issue
- 23
- Pages
- 3799-3808
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2125732268
- Cited by
- 286
- References
- 103
- FWCI
- 7.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.